FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

Cancer Immunology, Immunotherapy

Volumn 63, Issue 11, 2014, Pages 1189-1197

  Braga, Walter Moises Tobias ^a   da Silva, Bruna Raphaeli ^a   de Carvalho, Ana Carolina ^a   Maekawa, Yumi H ^b   Bortoluzzo, Adriana Bruscato ^c   Rizzatti, Edgar Gil ^b   Atanackovic, Djordje ^d   Colleoni, Gisele Wally Braga ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

^c INSPER INSTITUTE OF EDUCATION AND RESEARCH   (Brazil)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

CTLA4; FOXP3; Multiple myeloma; Therapy; Treg

Indexed keywords

BIOLOGICAL MARKER; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SYNDECAN 1;

ADULT; AGED; BONE MARROW; BONE MARROW CELL; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METABOLISM; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; PLASMACYTOMA; REGULATORY T LYMPHOCYTE; TH17 CELL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE MARROW; BONE MARROW CELLS; CTLA-4 ANTIGEN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PLASMACYTOMA; SYNDECAN-1; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TREATMENT OUTCOME;

EID: 84924920584     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1589-9     Document Type: Article

References (37)

1. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563–579. doi:10.1111/j.1365-2141.2007.06705.x
2. Prabhala RH, Neri P, Bae JE, Tassone J, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301–304. doi:10.1182/blood-2005-08-3101
3. O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nat Med 10:801–805. doi:10.1038/nm0804-801
4. Adeegbe DO, Nishikawa H (2013) Natural and induced T regulatory cells in cancer. Front Immunol 4:190. doi:10.3389/fimmu.2013.00190
5. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok J (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105:20410–20415. doi:10.1073/pnas.0810114105
6. Gupta R, Ganeshan P, Hakim M, Verma R, Sharma A (2011) Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 35:874–878. doi:10.1016/j.leukres.2010.11.010
7. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA, Classen S, Schultze JL (2006) In vivo peripheral expansion of naive CD4+ CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107:3940–3949. doi:10.1182/blood-2005-09-3671
8. + double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144:686–695. doi:10.1111/j.1365-2141.2008.07530.x
9. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS, Watowich SS, Feng XH, Jetten AM, Dong C (2008) Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29:44–56. doi:10.1016/j.immuni.2008.05.007
10. Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC (2010) Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115:5385–5392. doi:10.1182/blood-2009-10-246660
11. Yang XO, Pappu B, Nurieva R, Akimzhanov A, Kang SH, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns K, Watowich SS, Tian Q, Jetten AM, Dong C (2008) TH17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28:29–39. doi:10.1016/j.immuni.2007.11.016.11
12. Li L, Patsoukis N, Petkova V, Boussiotis VA (2012) Runx1 and runx3 are involved in the generation and function of highly suppressive IL-17-producing T regulatory cells. PLoS ONE 7:e45115. doi:10.1371/journal.pone.0045115
13. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112:2878–2885. doi:10.1182/blood-2008-03-143222
14. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757
15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420. doi:10.1200/JCO.2005.04.242
16. Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, de Chauffaille ML, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL (2009) SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis. Cancer Lett 278:41–48. doi:10.1016/j.canlet.2008.12.022
17. Ayukawa H, Matsubara T, Kaneko M, Hasegawa M, Ichiyama T, Furukawa S (2004) Expression of CTLA-4 (CD152) in peripheral blood T cells of children with influenza virus infection including encephalopathy in comparison with respiratory syncytial virus infection. Clin Exp Immunol 137(1):151–155. doi:10.1111/j.1365-2249.2004.02502.x
18. + regulatory T-cells in hematologic diseases. Korean J Lab Med 31:231–237. doi:10.3346/jkms.2012.27.9.1009
19. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW (2008) Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 8:2
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. doi:10.1006/meth.2001.1262
21. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114:1141–1149. doi:10.1182/blood-2009-03-208249
22. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811. doi:10.1182/blood-2006-02-002774
23. Pessoa de Magalhães RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, García-Sanz R, Mateos MV, Gutierrez NC, Lecrevisse Q, Blanco JF, Hernández J, de las Heras N, Martinez-Lopez J, Roig M, Costa ES, Ocio EM, Perez-Andres M, Maiolino A, Nucci M, De La Rubia J, Lahuerta JJ, San-Miguel JF, Orfao A, Spanish Myeloma Group (GEM), Grupo Castellano-Leones de Gammapatias Monoclonales, cooperative study groups (2013) Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98:79–86. doi:10.3324/haematol.2012.067272
24. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354. doi:10.1093/intimm/dxm014
25. Liu J, Lluis A, Illi S, Layland L, Olek S, von Mutius E, Schaub B (2010) T regulatory cells in cord blood—FOXP3 demethylation as reliable quantitative marker. PLoS ONE 5:e13267. doi:10.1371/journal.pone.0013267
26. + T regulatory cells in anergic lepromatous leprosy patients. PLoS Negl Trop Dis 8:e2639. doi:10.1371/journal.pntd.0002639
27. reg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291–1297. doi:10.1182/blood-2006-02-003996
28. HungriaVT, Maiolino A, Martinez G, Colleoni GW, Coelho EO, Rocha L, Nunes R, Bittencourt R, Oliveira LC, Faria RM, Pasquini R, Magalhães SM, Souza CA, Pinto Neto JV, Barreto L, Andrade E, Portella MS, Bolejack V, Durie BG, International Myeloma Working Group Latin America (2008) Confirmation of the utility of the international staging system and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica 93(5):791–792. doi:10.3324/haematol.11637
29. Giannopoulos K, Kaminska W, Hus I, Dmoszynska A (2012) The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 106:546–552. doi:10.1038/bjc.2011.575
30. Raja KRM, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R (2012) Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS ONE 7(10):e47077. doi:10.1371/journal.pone.004707
31. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Izawa S, Fujii H (2010) Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101:1947–1954. doi:10.1111/j.1349-7006.2010.01624.x
32. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+ CD25− naïve T cells to CD4+ CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 198:1875–8186. doi:10.1084/jem.20030152
33. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H (2005) Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6:1219–1227. doi:10.1038/ni1265
34. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR (2008) TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature 453:236–240. doi:10.1038/nature06878
35. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517. doi:10.1146/annurev.immunol.021908.132710
36. Guichelaar T, Emmelot ME, Rozemuller H, Martini B, Groen RW, Storm G, Lokhorst HM, Martens AC, Mutis T (2013) Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells. Clin Cancer Res 19:1467–1475. doi:10.1158/1078-0432.CCR-12-2177
37. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3 Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113:6102–6111. doi:10.1182/blood-2008-12-195354